AELIS Share Price Performance
€1.23
-2.85 (-69.98%)
Price €1.23
Share Price€1.23
We Think Some Shareholders May Hesitate To Increase Aelis Farma SA's (EPA:AELIS) CEO Compensation
May 21
Aelis Farma SA Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
AELIS Community Narratives
There are no narratives available yet.
Recent AELIS News & Updates
Aelis Farma SA Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.60
- Gross Margin
- 100.00%
- Net Profit Margin
- -351.31%
- Debt/Equity Ratio
- 96.3%
Aelis Farma SA Competitors
Snowflake Analysis
About AELIS
- Founded
- 2013
- Employees
- 24
- CEO
- WebsiteView website
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive impairments. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
French Market Performance
- 7 Days: 1.1%
- 3 Months: 0.8%
- 1 Year: 4.4%
- Year to Date: 6.1%
The market has climbed 1.1% in the last 7 days, lead by the Consumer Discretionary sector with a gain of 4.7%. The market is up 4.4% over the last 12 months. Earnings are forecast to grow by 12% annually. Market details ›